

Press release

LEUKOCARE to receive Frost & Sullivan's prestigious 2011 Biotechnology Investment Opportunity Award

Munich, Germany, 14.02.2012

LEUKOCARE, a leading provider of stabilizing technologies for proteins and vaccines, has been awarded 2011's "Biotechnology Investment Opportunity Award", by the independent research consultancy Frost & Sullivan.

In the citation for the *2011 European Biotechnology Industry Early Stage Investment Opportunity Award*, Frost & Sullivan focuses on the innovative nature of LEUKOCARE's Stabilizing and Protecting Solutions (SPS) and the company's strong strategic position in fast growing markets. The award report concludes: "LEUKOCARE, by way of its early mover advantage, its path breaking technology and sound management backing, is well positioned to be the recipient of Frost & Sullivan's 'Investment Opportunity' award."

"We are honoured that distinguished global analyst firm Frost & Sullivan recognises our achievements and emphasizes the outstanding value our expertise has created by helping companies maintain the stability, sterility, and shelf life of their delicate biological molecules," says Michael Scholl, CEO with LEUKOCARE. "This prestigious award gives us a tremendous incentive to forge ahead, especially in fast growing markets, where we have already made great progress."

About LEUKOCARE

LEUKOCARE is a leading provider of technologies for biological functionalization of medical devices, as well as the stabilization and protection of proteins and biological molecules in biopharmaceutical formulations in order to ensure safety, to extend shelf-life and to enable terminal sterilization.

As a product-focused biotechnology company, LEUKOCARE uses its proprietary Stabilizing and Protecting Solutions (SPS) to leverage its comprehensive expertise in industrial co-development partnerships. The company offers its know-how in formulation of biologics, biofunctional coatings of combination devices and product development.

LEUKOCARE was founded in 2003 and is headquartered in Martinsried near Munich, Germany. For further information, please visit www.LEUKOCARE.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies.

Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. For further information, please visit www.frost.com.

Notes for editors:

Many biologics are prone to degradation as well as destabilization or unfolding in response to chemical and physical processes during production, sterilization and storage. Thus, safety, shelf life and sterilization are key bottlenecks in the design strategies and market success of new products. LEUKOCARE's Stabilizing and Protecting Solutions (SPS) increase product quality and safety by combining stabilizing and protecting properties in one single product.

Michael Scholl

CEO

Phone: +49 (0)89 780 16 65 – 0

Fax: +49 (0)89 780 16 65 – 11

Email: michael.scholl@leukocare.com